Method of identifying a MHC class I restricted T cell response
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 22, 2011
Grant Date -
Oct 7, 2010
app pub date -
Oct 13, 2009
filing date -
Sep 8, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully